Search Results - "Jing, Weiqing"

Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma by Kearl, Tyce J, Jing, Weiqing, Gershan, Jill A, Johnson, Bryon D

“…Early phase clinical trials targeting the programmed death receptor-1/ligand-1 (PD-1/PD-L1) pathway to overcome tumor-mediated immunosuppression have reported…”
Get full text

Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors by Xin, Gang, Schauder, David M., Jing, Weiqing, Jiang, Aimin, Joshi, Nikhil S., Johnson, Bryon, Cui, Weiguo

“…Because of insufficient migration and antitumor function of transferred T cells, especially inside the immunosuppressive tumor microenvironment (TME), the…”
Get full text

T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia by Jing, Weiqing, Gershan, Jill A, Holzhauer, Sandra, Weber, James, Palen, Katie, McOlash, Laura, Pulakanti, Kirthi, Wesley, Erin, Rao, Sridhar, Johnson, Bryon D, Riese, Matthew J

“…Efforts to improve the efficacy of adoptive T-cell therapies and immune checkpoint therapies in myelogenous leukemia are desired. In this study, we evaluated…”
Get full text

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma by Jing, Weiqing, Gershan, Jill A, Weber, James, Tlomak, Dominique, McOlash, Laura, Sabatos-Peyton, Catherine, Johnson, Bryon D

“…Multiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the bone marrow and is generally considered to be an incurable…”
Get full text

Targeting transmembrane-domain-less MOG expression to platelets prevents disease development in experimental autoimmune encephalomyelitis by Cai, Yuanhua, Schroeder, Jocelyn A, Jing, Weiqing, Gurski, Cody, Williams, Calvin B, Wang, Shaoyuan, Dittel, Bonnie N, Shi, Qizhen

“…Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system with no cure yet. Here, we report genetic engineering of…”
Get full text

Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory by Jing, Weiqing, Gershan, Jill A., Johnson, Bryon D.

“…High-risk neuroblastoma remains a clinically challenging disease. Here, we report that a multifaceted immunotherapeutic approach including syngeneic…”
Get full text

Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice by Gao, Chunyan, Schroeder, Jocelyn A., Xue, Feng, Jing, Weiqing, Cai, Yuanhua, Scheck, Amelia, Subramaniam, Saravanan, Rao, Sridhar, Weiler, Hartmut, Czechowicz, Agnieszka, Shi, Qizhen

“…Gene therapy offers the potential to cure hemophilia A (HA). We have shown that hematopoietic stem cell (HSC)–based platelet-specific factor VIII (FVIII)…”
Get full text

1051 Noval IL-12 gene delivery vehicles for transformation of spontaneous canine soft-tissue sarcoma by Jing, Weiqing, Shinglot, Himaly, Kei Ng, Juliana Chi, Zhang, Ali, Al-Marayaty, Rusul, Wu, Jennifer, Bryan, Jeffrey, Pollack, Seth

“…BackgroundInterleukin 12 (IL-12) is a highly inflammatory cytokine that has potent activity in cancer, which mediates its antitumor activity through both…”
Get full text

Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma by Jing, Weiqing, Yan, Xiaocai, Hallett, William H.D., Gershan, Jill A., Johnson, Bryon D.

“…A multifaceted immunotherapeutic strategy that includes hematopoietic stem cell (HSC) transplantation, T-cell adoptive transfer, and tumor vaccination can…”
Get full text

Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice by Jing, Weiqing, Chen, Juan, Cai, Yuanhua, Chen, Yingyu, Schroeder, Jocelyn A., Johnson, Bryon D., Cui, Weiguo, Shi, Qizhen

“…The development of neutralizing anti-FVIII antibodies (inhibitors) is a major complication of FVIII protein replacement therapy in patients with hemophilia A…”
Get full text

Adoptive cell therapy using PD-1 + myeloma-reactive T cells eliminates established myeloma in mice by Jing, Weiqing, Gershan, Jill A, Blitzer, Grace C, Palen, Katie, Weber, James, McOlash, Laura, Riese, Matthew, Johnson, Bryon D

“…Adoptive cellular therapy (ACT) with cancer antigen-reactive T cells following lymphodepletive pre-conditioning has emerged as a potentially curative therapy…”
Get full text

CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma by JOHNSON, Bryon D, WEIQING JING, ORENTAS, Rimas J

“…Evidence that CD4CD25 regulatory T (Treg) cells play a role in the progression of cancer continues to mount. There is a great deal of interest as to whether…”
Get full text

Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade by Zheng, Jin, Jing, Weiqing, Orentas, Rimas J.

“…Neuroblastoma is one of the most common solid tumors in infancy and early childhood. Using the A/J mouse and a syngeneic neuroblastoma cell line AGN2a, we…”
Get full text

Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors by Chen, Yingyu, Li, Jing, Schroeder, Jocelyn A., Jing, Weiqing, Shi, Qizhen

“…Platelet gene therapy is effective in hemophilia A (HA) mice even with inhibitors. Fludarabine (Flu), along with busulfan (Bu) or melphalan (Mel),…”
Get full text

The Tfh/Tfr Pathway Is Pivotal in FVIII Inhibitor Development in Mice by Jing, Weiqing, Schroeder, Jocelyn, Chen, Juan, Cai, Yuanhua, Kumar, Saurabh, Dent, Alexander, Shi, Qizhen

“…The development of neutralizing anti-FVIII antibodies (inhibitors) is one major complication of FVIII protein replacement therapy in hemophilia A patients. Our…”
Get full text

Melanoma patients respond to a new HLA‐A01‐presented antigenic ligand derived from a multi‐epitope region of melanoma antigen TRP‐2 by Paschen, Annette, Jing, Weiqing, Drexler, Ingo, Klemm, Moritz, Song, Mingxia, Müller‐Berghaus, Jan, Nguyen, Xuan Duc, Osen, Wolfram, Stevanovic, Stefan, Sutter, Gerd, Schadendorf, Dirk

“…Tyrosinase‐related protein‐2 (TRP‐2) is a known target antigen of spontaneous cytotoxic T cell responses in melanoma patients. Its frequent expression in…”
Get full text

Pre-Existing Anti-FVIII Immunity Alters Therapeutic Platelet-Targeted FVIII Engraftment in the System Preconditioned with Busulfan Alone through Cytotoxic CD8 T Cells by Jing, Weiqing, Baumgartner, Christina, Xue, Feng, Schroeder, Jocelyn A., Shi, Qizhen

“…The development of anti-FVIII inhibitory antibodies (inhibitors) is a significant problem in FVIII protein replacement therapy in hemophilia A (HA). We have…”
Get full text

Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells by Jing, Weiqing, Baumgartner, Christina K., Xue, Feng, Schroeder, Jocelyn A., Shi, Qizhen

“…We previously demonstrated that busulfan preconditioning enabled sustained therapeutic platelet-derived factor VIII (FVIII) expression in naïve FVIIInull mice…”
Get full text

Fludarabine in Combination with Busulfan As Pretransplant Conditioning for Platelet Gene Therapy in Murine Hemophilia a with Inhibitors by Chen, Yingyu, Li, Jing, Schroeder, Jocelyn A., Jing, Weiqing, Hu, Jianda, Shi, Qizhen

“…Treatment of hemophilia A (HA) with inhibitors is costly, inconvenient, and incompletely effective. We have demonstrated that syngeneic transplantation of…”
Get full text

Induction of Activated T Follicular Helper Cells Is Critical for Anti-FVIII Inhibitor Development in Hemophilia a Mice by Jing, Weiqing, Chen, Juan, Cai, Yuanhua, Chen, Yingyu, Schroeder, Jocelyn A., Cui, Weiguo, Shi, Qizhen

“…The development of neutralizing anti-FVIII antibodies (inhibitors) is one major complication of FVIII protein replacement therapy in hemophilia A patients…”
Get full text